Table 2 Summary of selected studies (number of study)
| Â | Â | ACEIs (total 6) | ARBs (total 33) | ARBs Losartan (total 14) | ARBs Irbesartan (total 18) | ARBs Valsartan (total 1) |
|---|---|---|---|---|---|---|
Data source | Trial based | 0 | 33 | 14 | 18 | 1 |
Literature based | 6 | 0 | 0 | 0 | 0 | |
Intervention and control group | Comparing with placebo/conventional therapy | 2 | 22 | 14 | 8 | 0 |
Comparing with other drugs | 0 | 12 | 0 | 11 | 1 | |
Comparing different strategies | 4 | 10 | 0 | 10 | 0 | |
Decision model | Markov model | 6 | 20 | 1 | 18 | 1 |
Weibull model | 0 | 3 | 3 | 0 | 0 | |
Regression method | 0 | 10 | 10 | 0 | 0 | |
Perspective | Third party payer | 4 | 33 | 14 | 18 | 1 |
Societal | 2 | 0 | 0 | 0 | 0 | |
CE results | Cost-saving | 5 | 32 | 13 | 18 | 1 |
Cost-neutral | 0 | 1 | 1 | 0 | 0 | |
Very cost-effective | 1 | 0 | 0 | 0 | 0 | |
Cost-effective | 0 | 0 | 0 | 0 | 0 | |
Not cost-effective | 0 | 0 | 0 | 0 | 0 |